Alnylam Pharmaceuticals Inc - 02142 Cambridge, MA

Business Name: Alnylam Pharmaceuticals Inc
Categorized In:
Address: 300 3rd St # 3, Cambridge, MA 02142
Phone Number: (617) 551-8200
Contact Person: John Maraganore, Chief Executive Officer
Website Address: alnylam.com
NAICS Code: 3254120
SIC Code: 2834
Business Type: B2B & B2C
Founding Year: 2002
Employee #: 1 to 4
Location Type: Headquarters
Annual Revenue ($): Unknown
Share This Business:
Similar Businesses: Il Pharma Inc - Cambridge, MA 02142
Newco Ls13 - Cambridge, MA 02142
Sanofi Us Services Inc - Cambridge, MA 02142
Shape Pharmaceuticals Inc - Cambridge, MA 02142
Verastem Inc - Cambridge, MA 02142
Targanta Therapeutics Corporation - Cambridge, MA 02142
Edimer Pharmaceuticals - Cambridge, MA 02142
Eleven Biotherapeutics - Cambridge, MA 02142
Constellation Pharmaceuticals - Cambridge, MA 02142
Millennium Pharmaceuticals - Cambridge, MA 02142
Aegerion Pharmaceuticals Inc - Cambridge, MA 02142
Via Cord LLC - Cambridge, MA 02142
Lipomed Inc - Cambridge, MA 02142
Ironwood Pharmaceuticals Inc - Cambridge, MA 02142
Momenta Pharmaceuticals Inc - Cambridge, MA 02142
Sarepta Therapeutics Inc - Cambridge, MA 02142
Zalicus Inc - Cambridge, MA 02142
Clarus Ventures LLC - Cambridge, MA 02142
Gloucester Pharmaceuticals Inc - Cambridge, MA 02142
Akanas Therapeutics Inc - Cambridge, MA 02142

Alnylam Pharmaceuticals Inc provides professional from its headquarters at the coordinates 42.36698,-71.08159.

The company offers BOTH variables under the SIC code 2834 and NAICS code 3254120, while making an annual revenue of Unknown and hiring a total of 1 to 4 employees.

Founded in 2002, the company can now be visited at 300 3rd St # 3, Cambridge, Massachusetts 02142 or contacted through representative John Maraganore, Chief Executive Officer at (617) 551-8200.

For frequently asked questions and further inquiries about professional , get to know more about Alnylam Pharmaceuticals Inc through its company website at alnylam.com. Engage with this business on its social media platforms through on Twitter and on Facebook.